Pınar YILDIZ GÜLHAN, Fatma YILDIRIM, Meltem ŞİMŞEK

COVID-19 ilişkili akut solunum sıkıntısı sendromu: Patolojik, radyolojik ve klinik durum

Ağır koronavirüs 2019 hastalığı (COVID-19), akut solunum sıkıntısı sendromuna (ARDS) yol açan ağır akut solunumsal sendrom koronavirüs 2 (SARS‐CoV‐2) enfeksiyonundan kaynaklanan viral pnömoniyi temsil eder. Ancak ARDS, COVID-19’un bir parçası olarak ortaya çıktığında farklı özellikler göstermektedir. Solunum destek tedavi stratejileri, COVID-19 ilişkili ARDS (CARDS) tedavisinde çok önemlidir. CARDS Berlin tanımını karşılasa da COVID-19 pnömonisi farklı fenotiplere sahip spesifik bir hastalıktır. Son zamanlarda, CARDS’ın tip L (Tip 1 veya ARDS olmayan) ve tip H (Tip 2, ARDS) olmak üzere iki fenotipe sahip olduğu ve bu fenotiplerin solunum destek tedavilerine farklı yanıt verdiği öne sürülmüştür. Bu derlemede, CARDS’ın patofizyolojisi ve radyolojik ilişkisinden bahsedildikten sonra iki farklı CARDS formunun tanımı ve tedavi yaklaşımları tartışılmıştır.

COVID-19 related acute respiratory distress syndrome: Pathological, radiological and clinical concordance

Severe coronavirus 2019 disease (COVID-19) represents viral pneumonia from severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection leading to acute respiratory distress syndrome (ARDS). However, when ARDS occurs as part of COVID‐19, it has different features. The strategy of breathing support is very important in treating COVID‐19 related ARDS (CARDS). Though it meets the CARDS Berlin definition, COVID-19 pneumonia is a specific disease with different phenotypes. Recently, it has been suggested that CARDS has two phenotypes, type L (Type 1 or non-ARDS) and type H (Type 2, ARDS), and these phenotypes respond differently to respiratory support treatments. In this review, after mentioning the pathophysiology and radiological relationship of CARDS, the definition and treatment approaches of two different forms of CARDS were discussed.

PDF

___

1. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L et al. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med 2020; 46(6): 1099-102.
2. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med 2020; 201(10): 1299-300.
3. Li X, Ma X. Acute respiratory failure in COVID-19: is it “typical” ARDS? Crit Care 2020; 24(1): 198.
4. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323(16): 1574- 81.
5. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020; 323(16): 1612-4.
6. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical Characteristics of Coronavirus Disease 2019 (COVID- 19). J Gen Intern Med 2020; 35(5): 1545-49.
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; 323(11): 1061-9.
8. Wichmann D, Sperhake J, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Diagn Pathol 2020; 15(1): 103.
9. Menter T, Haslbauer J, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Post-mortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology 2020; 77(2): 198-209.
10. Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol; 33(6): 1007-14.
11. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4): 420-2.
12. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol 2020; 30(8): 4381-9.
13. Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers 2019; 5(1): 18.
14. Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: A pathological review for clinicians. Respir Med 2021; 176: 106239.
15. Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA 2020; 323(22): 2329-30.
16. Robba C, Battaglini D, Ball L, Patroniti N, Loconte M, Brunetti I, et al. Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. Respir Physiol Neurobiol 2020; 279: 103455.
17. Navas-Blanco JR, Dudaryk R. Management of respiratory distress syndrome due to COVID-19 infection. BMC Anesthesiol 2020; 20(1): 177.
18. Beloncle FM, Pavlovsky B, Desprez C, Fage N, Olivier PY, Asfar P, et al. Recruitability and effect of PEEP in SARSCov- 2-associated acute respiratory distress syndrome. Ann Intensive Care 2020; 10(1): 55.